Effectiveness of bupropion on sexual dysfunction of women with multiple sclerosis: A Clinical Trial

Document Type : Original Article

Authors

1 Resident, Department of Psychiatry, Behavioral Sciences Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Professor, Department of Psychiatry, Behavioral Sciences Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Physician, Neuroscience Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan.

4 Associate Professor, Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.

5 Professor, Department of Psychiatry, Behavioral Science Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

6 Professor, Department of Neurology, Neuroscience Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

7 Assistant Professor, Department of Research, Behavioral Sciences Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Introduction: Sexual dysfunctions are relatively prevalent in female patients with multiple sclerosis (MS) and affect their quality of life. This study was performed with aim to evaluate the effect of Bupropion on sexual function in women with multiple sclerosis.
Methods: This randomized controlled clinical trial study was performed in 2019 on 60 women with relapsing and remitting MS, receiving routine MS treatment and had sexual dysfunction. The subjects were divided to two groups of 30 persons receiving Bupropion and placebo. Multiple sclerosis intimacy and sexuality questionnaire, female sexual function index, fatigue severity scale and Beck depression questionnaire were filled out for all the patients before, 4 and 8 weeks after the interventions initiation. Data were analyzed by SPSS software (version 20) and Analysis of variance (AOVA) and repeated measure tests. P<0.05 was considered statistically significant.
Results: Multiple sclerosis intimacy and sexuality scores 8 weeks after the intervention were significantly lower in bupropion group (9.96±45.85) compared to placebo group (53.56±11.46) (P= 0.007). Also, the score of depression in the two stages after the intervention in the bupropion group (11.26 ± 23.03) was lower than the placebo group (37.86 ± 13.43) and decreased during the intervention (p <0.0001). FSFI score and its subscales showed an improvement in bupropion group (2.67±25.88) compared with placebo group (17.44±2.8) which indicated continuity of effectiveness of Bupropion independently from depression and fatigue scores alteration during treatment (p<0.001).
Conclusion: The results of the present study showed the effectiveness of bupropion on improvement of sexual function in female patients with MS.

Keywords

References

  1. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nature Reviews Immunology 2015; 15(9):545-58.
  2. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris) 2016; 172(1):3-13.
  3. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 2013; 19(2 Suppl):S15-20.
  4. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis. Neuroepidemiology 2015; 44(4):232-44.
  5. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83(3):278-86.
  6. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014; 13(7):700-9.
  7. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 2013; 13(12 Suppl):3-9.
  8. Lassmann H. Multiple Sclerosis Pathology. Cold Spring Harb Perspect Med 2018; 8(3):a028936.
  9. Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) 2013; 19(4 Multiple Sclerosis):901-21.
  10. Celik DB, Poyraz EÇ, Bingöl A, Idiman E, Ozakbaş S, Kaya D. Sexual dysfunction ın multiple sclerosis: gender differences. J Neurol Sci 2013; 324(1-2):17-20.
  11. Mohammadi K, Rahnama P, Mohseni SM, Sahraian MA, Montazeri A. Determinants of sexual dysfunction in women with multiple sclerosis. BMC Neurol 2013; 13:83.
  12. Kisic-Tepavcevic D, Pekmezovic T, Trajkovic G, Stojsavljevic N, Dujmovic I, Mesaros S, et al. Sexual dysfunction in multiple sclerosis: A 6-year follow-up study. J Neurol Sci 2015; 358(1-2):317-23.
  13. Lew-Starowicz M, Gianotten WL. Sexual dysfunction in patients with multiple sclerosis. Handb Clin Neurol 2015; 130:357-70.
  14. Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI. Bupropion and bupropion analogs as treatments for CNS disorders. Adv Pharmacol 2014; 69:177-216.
  15. Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. CMAJ 2014; 186(13):1015.
  16. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Primary care companion to the Journal of clinical psychiatry 2005; 7(3):106.
  17. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013; 21(5):935-43.
  18. López HH, Wurzel G, Ragen B. The effect of acute bupropion on sexual motivation and behavior in the female rat. Pharmacol Biochem Behav 2007; 87(3):369-79.
  19. Modell JG, May RS, Katholi CR. Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J Sex Marital Ther 2000; 26(3):231-40.
  20. Taylor Segraves, Harry Croft, Richard Kavoussi, John A. Ascher, Sharyn R. Batey, Vicki J. Foster, Carolyn Bolden-Watson, Alan Metz R. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. Journal of Sex &Marital Therapy 2001; 27(3):303-16.
  21. Siniscalchi A, Gallelli L, Tolotta GA, Loiacono D, De Sarro G. Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. Clinical therapeutics 2010; 32(12):2030-4.
  22. Safarinejad MR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. Journal of Psychopharmacology 2011; 25(3):370-8.
  23. Neijenhuijs KI, Hooghiemstra N, Holtmaat K, Aaronson NK, Groenvold M, Holzner B, Terwee CB, Cuijpers P, Verdonck-de Leeuw IM. The Female Sexual Function Index (FSFI)—a systematic review of measurement properties. The journal of sexual medicine 2019; 16(5):640-60.
  24. Sanders AS, Foley FW, LaRocca NG, Zemon V. The multiple sclerosis intimacy and sexuality questionnaire-19 (MSISQ-19). Sexuality and Disability 2000; 18(1):3-26.
  25. Mohammadi K, Rahnama P, Tabar SM, Montazeri A. Validation of the persian version of multiple sclerosis intimacy and sexuality questionnaire-19 (MSISQ-19). Payesh (Health Monitor) 2014; 13(5):601-7.
  26. Rosen C, Brown J, Heiman S, Leiblum C, Meston R, Shabsigh D, et al. D'Agostino R. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Journal of sex & marital therapy 2000; 26(2):191-208.
  27. Mohammadi Kh, Heydari M, Faghihzadeh S. The Female Sexual Function Index (FSFI): validation of the Iranian version. Payesh 2008; 7(3):269-278.
  28. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of neurology 1989; 46(10):1121-3.
  29. Shahvarughi-Farahani A, A'zimian M, Fallah-Pour M, Karimlou M. Evaluation of Reliability and Validity of the Persian Version of Fatigue Severity Scale (FSS) among Persons with Multiple Sclerosis. jrehab 2013; 13(4):84-91
  30. Azizi S, Ebrahimi MT, Shamshirian A, Houshmand S, Ebrahimi M, Seyyed Esmaeeli F, et al. Evaluation of the level of depression in students of School of Paramedic Sciences, Mazandaran University of Medical Sciences, in 2015. Tabari Biomedical Student Research Journal 2016; 1(3):41-8.
  31. Bendale M, DSouza SR, Addepalli V, Kale PP. The effect of bupropion augmentation of minocycline in the treatment of depression. Acta Neurobiol Exp (Wars) 2019; 79(2):217-224.
  32. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 2016; 6(2):99-144.
  33. Rezaei O, Fadai F, Sayadnasiri M, Palizvan MA, Armoon B, Noroozi M. The effect of bupropion on sexual function in patients with Schizophrenia: A randomized clinical trial. The European Journal of Psychiatry 2018; 32(1):11-5.
  34. Salehi M, Barekatain M, Faghani F, Karimian N, Molaeinezhad M, Asadalloahi GA, et al. Bupropion efficacy on sexual dysfunction among male patients on methadone maintenance therapy: a double-blind placebo-controlled trial. Sexual and Relationship Therapy 2015; 30(3):364-75.
  35. Ginzburg R, Wong Y, Fader JS. Effect of bupropion on sexual dysfunction. Ann Pharmacother 2005; 39(12):2096-9.
  36. Tatari F, Shakeri J, Farnia V, Heidari F, Rezaei M. Bupropion in methadone induced erectile dysfunction. Ann Psychiatry Ment Health 2014; 2(3):1015.
  37. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005; 66(7):844-8.
  38. Foley FW. Assessment and treatment of sexual dysfunction in multiple sclerosis. National Multiple Sclerosis Society Clinical Bulletin 2006; 8:1-1.
  39. Pöttgen J, Rose A, van de Vis W, Engelbrecht J, Pirard M, Lau S, et al. Sexual dysfunctions in MS in relation to neuropsychiatric aspects and its psychological treatment: A scoping review. PLoS One 2018; 13(2):e0193381.
  40. Yee A, Loh HS, Ong TA, Ng CG, Sulaiman AH. Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of Bupropion as Treatment for Methadone-Emergent Sexual Dysfunction in Men. Am J Mens Health 2018; 12(5):1705-1718.
  41. Zheng X, Hasegawa H. Central dopaminergic neurotransmission plays an important role in thermoregulation and performance during endurance exercise. Eur J Sport Sci 2016; 16(7):818-28.
  42. Carotenuto A, Wilson H, Giordano B, Caminiti SP, Chappell Z, Williams SCR, et al. Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. J Neurol 2020; 267(7):2042-2053.
  43. Ghoreishi A, Dashtaki L, Hajisalimi B. Bupropion as a treatment for sexual dysfunction among chronic kidney disease patients. Acta Medica Iranica 2019.

The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 24, Issue 2
April 2021
Pages 59-70

Files

Share

How to cite

Statistics